Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection

被引：0
|
作者：
Llenas-Garcia, Jara [1 ,2 ]
Padilla, Sergio [1 ,3 ]
Masia, Mar [1 ,3 ]
Gutierrez, Felix [1 ,3 ]
机构：
[1] Hosp Gen Univ Elche, Infect Dis Unit, Alicante, Spain
[2] Fdn Promot Hlth & Biomed Res Valencian Reg FISABI, Valencia, Spain
[3] Univ Miguel Hernandez, Alicante, Spain
来源：
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2018年 / 36卷 / 07期
关键词：
EFFICACY; SAFETY;
D O I：
10.1016/j.eimc.2017.10.012
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：457 / 457
页数：1
相关论文
共 50 条
  • [1] Compare the Efficacy of Sofosbuvir Plus Ribavirin Verus Sofosbuvir Plus Daclatasvir in Patients with Chronic C Hepatitis Genotype 2 Infection
    Chang, Kuo-Chin
    Hu, Tsung-Hui
    Chen, Chien Hung
    Wang, Jing-Houng
    [J]. HEPATOLOGY, 2018, 68 : 586A - 586A
  • [2] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus
    McEwan, Phil
    Webster, Samantha
    Ward, Thomas
    Brenner, Michael
    Kalsekar, Anupama
    Yuan, Yong
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [3] Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients
    Gevers, T. J. G.
    Burger, D.
    Schipper-Reintjes, E.
    Kooistra, M. P.
    Richter, C.
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 2016, 74 (05): : 225 - 227
  • [4] Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection
    Sundaram, Vinay
    Kowdley, Kris V.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (01) : 13 - 20
  • [5] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
    Ahmed, Ossama A.
    Elsebaey, Mohamed A.
    Fouad, Mohamed Hassan A.
    Elashry, Heba
    Elshafie, Ahmed I.
    Elhadidy, Ahmed A.
    Esheba, Noha E.
    Elnaggar, Mohammed H.
    Soliman, Shaimaa
    Abd-Elsalam, Sherief
    [J]. INFECTION AND DRUG RESISTANCE, 2018, 11 : 441 - 445
  • [6] Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
    Sperl, Jan
    Frankova, Sona
    Kreidlova, Miluse
    Merta, Dusan
    Tothova, Monika
    Spicak, Julius
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 733 - 738
  • [7] Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3
    Belperio, Pamela S.
    Shahoumian, Troy A.
    Loomis, Timothy P.
    Mole, Larry A.
    Backus, Lisa I.
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : 15 - 23
  • [8] Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis
    Abdel-Aziz, Asmaa M.
    Ibrahim, Mohamed A.
    El-Sheikh, Azza A.
    Kamel, Maha Y.
    Zenhom, Nagwa M.
    Abdel-Raheim, Salam
    Abdelhaleem, Hisham
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2018, 8 (01) : 15 - 22
  • [9] Evaluation of sofosbuvir plus daclatasvir combination for hepatitis C virus treatment
    Moron Romero, Rocio
    Diaz, Xando
    del Carmen Gonzalez, Maria
    Rodriguez, Alejandro
    Casas, Inmaculada
    Cabeza, Jose
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 331 - 331
  • [10] Sofosbuvir Plus Daclatasvir for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis
    Saadoun, David
    Ferfar, Yasmina
    Bouyer, A. S.
    Alric, Laurent
    Hezode, Christophe
    Ahmed, S. N. Si
    Musset, L.
    Pernot, Luc De Saint Martin
    Pol, S. N.
    Larrey, Dominique
    Poynard, T.
    Cacoub, Patrice
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345